Non-Small-Cell Lung cancer (NSCLC) – Pipeline Insight, 2021

 Breaking News
  • No posts were found

Non-Small-Cell Lung cancer (NSCLC) – Pipeline Insight, 2021

April 16
21:34 2021
Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2021

NSCLC Pipeline” report has been added to DelveInsight

NSCLC Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of NSCLC pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

Download free sample copy here-

DelveInsight’s, “Non-Small-Cell Lung cancer (NSCLC) – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Non-Small-Cell Lung cancer (NSCLC): Overview

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.

NSCLC Pipeline Report

NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC.

NSCLC Emerging Drugs

  • AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

  • CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

NSCLC Treatment

Currently the mainstay of treatment is immune checkpoint inhibitors, combination of targeted and immunotherapy with chemotherapy. Although in future, scenario is going to be changed as most of the companies are targeting specific mutations to treat the NSCLC patients.

Growth of NSCLC Market is expected to be driven by increasing incident case of NSCLC, continue uptake of approved therapies mainly immune checkpoint inhibitors, expected entry of potential premium price emerging therapies and increasing awareness of mutations like BRAF, c-Met and others; currently there is a lack of potential treatment options for these mutations but now companies are working thoroughly towards the development of mutation specific therapies.

NSCLC Emerging Therapy Assessment

The emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanism of action for the treatment of patients affected with NSCLC.

NSCLC Key Players

  • Genentech
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech/Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Bayer Healthcare
  • Eli Lilly
  • And many others


  • Rozlytrek
  • Imfinzi
  • Opdivo
  • Tecentriq (Atezolizumab):
  • And many others

NSCLC Report Insights

  • Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Following is the TOC of NSCLC Pipeline report

  • Introduction
  • Executive Summary
  • Non-Small-Cell Lung cancer (NSCLC): Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Late Stage Products (Pre-Registration)
  • AMG 510: Amgen
  • Mid Stage Products (Phase II)
  • Drug Name: Company Name
  • Early Stage Products (Phase I)
  • CMP 001: Cytos Biotechnology
  • Inactive Products
  • Non-Small-Cell Lung cancer (NSCLC) Key Companies
  • Non-Small-Cell Lung cancer (NSCLC) Key Products
  • Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  • Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  • Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  • Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  • Non-Small-Cell Lung cancer (NSCLC) Key Companies
  • Appendix


What are the key questions answered?

  • How many companies are developing Non-Small-Cell Lung cancer (NSCLC) drugs?
  • How many Non-Small-Cell Lung cancer (NSCLC) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small-Cell Lung cancer (NSCLC)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Small-Cell Lung cancer (NSCLC) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non-Small-Cell Lung cancer (NSCLC) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles